Literature DB >> 17992092

Therapies for narcolepsy with or without cataplexy: evidence-based review.

Susan Keam1, Matthew C Walker.   

Abstract

(1) Narcolepsy is a rare disorder of unknown aetiology characterized by excessive daytime sleepiness and typically associated with cataplexy. It is extremely incapacitating, and frequently results in impaired psychosocial functioning and reduced work performance. Currently there is no cure for narcolepsy, so treatment focuses on control of symptoms.(2) Although the sympathomimetic stimulants, such as amphetamines or methylphenidate, are effective in improving excessive daytime sleepiness in patients with narcolepsy, they have the potential for dependence, have sometimes disabling sympathomimetic side-effects and are associated with tolerance.(3) To date, there is clear evidence of the efficacy of modafinil, armodafinil and sodium oxybate in patients with narcolepsy. Modafinil and armodafinil improve excessive daytime sleepiness symptoms and have little abuse potential, but have no effect on cataplexy, so other drugs, such as antidepressants, are required to control cataplexy attacks.(4) Sodium oxybate improves both excessive daytime sleepiness and cataplexy. However, there is potential for abuse and possibly dependence.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17992092     DOI: 10.1097/WCO.0b013e3282f22ad9

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  6 in total

1.  Effect of Oral JZP-110 (ADX-N05) on Wakefulness and Sleepiness in Adults with Narcolepsy: A Phase 2b Study.

Authors:  Chad Ruoff; Todd J Swick; Robert Doekel; Helene A Emsellem; Neil T Feldman; Russell Rosenberg; Gary Bream; Moise A Khayrallah; Yuan Lu; Jed Black
Journal:  Sleep       Date:  2016-07-01       Impact factor: 5.849

Review 2.  Sodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysis.

Authors:  Mashael K Alshaikh; Andrea C Tricco; Mariam Tashkandi; Muhammad Mamdani; Sharon E Straus; Ahmed S BaHammam
Journal:  J Clin Sleep Med       Date:  2012-08-15       Impact factor: 4.062

3.  Armodafinil in the treatment of sleep/wake disorders.

Authors:  Jonathan R L Schwartz; Thomas Roth; Chris Drake
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

4.  Relationship between sleep efficacy endpoints and measures of functional status and health-related quality of life in participants with narcolepsy or obstructive sleep apnea treated for excessive daytime sleepiness.

Authors:  Terri E Weaver; Susan D Mathias; Ross D Crosby; Morgan Bron; Shay Bujanover; Diane Menno; Kathleen F Villa; Christopher Drake
Journal:  J Sleep Res       Date:  2020-10-13       Impact factor: 3.981

5.  Narcolepsy: current treatment options and future approaches.

Authors:  Michel Billiard
Journal:  Neuropsychiatr Dis Treat       Date:  2008-06       Impact factor: 2.570

6.  Effects of hypocretin/orexin cell transplantation on narcoleptic-like sleep behavior in rats.

Authors:  Oscar Arias-Carrión; Eric Murillo-Rodríguez
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.